Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 ФГБУ «НМИЦ ПН им. В. П. Сербского» Минздрава России, г. Москва 2 ФКГУ «1586 военный клинический госпиталь» МО РФ
Список исп. литературыСкрыть список 1. Caccia S, Invernizzi RW, Nobili A, Pasina L., А new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia//dovepress 2013:9 Pages 319–328. 2. Citrome L Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.// Clin Schizophr Relat Psychoses. 2016 Summer;10(2):109-19. doi: 10.3371/1935-1232-10.2.109. Review. 3. Cutler AJ, Durgam S, Wang Y, Migliore R2, Lu K2, Laszlovszky I4, Németh G4, Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study// CNS Spectr. 2018 Feb;23(1):39-50. doi: 10.1017/S1092852917000220. 4. Debelle M, Németh G, Szalai E, Szatmári B, Harsányi J, Barabássy A, Laszlovszky I. (2015) Cariprazine as monotherapy for the treatment of schizophrenia patients with predominant negative symptoms: a double-blind, active controlled trial. //Eur Neuropsychopharamcol 25:S510. [Google Scholar]. 5. Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, Wolfgang Fleischhacker W, Nasrallah HA, Corrigendum to "Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial"//Schizophr Res. 2018 Feb;192:493. doi: 10.1016/j.schres.2017.04.020. Epub 2017 Apr 18. 6. Vanja Duric,1 Mounira Banasr,1 Tina Franklin,1 Ashley Lepack,1 Nika Adham,1 Béla Kiss,1 István Gyertyán,1 and Ronald S. Duman Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model//Int J Neuropsychopharmacol. 2017 Oct 1;20(10):788-796. doi: 10.1093/ijnp/pyx038. 7. Frankel JS1, Schwartz TL Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole // Ther Adv Psychopharmacol. 2017 Jan; 7(1): 29–41. 8. Freedman SB, Patel S, Marwood R, et al. Expression and pharmacological characterization of the human D3 receptor. //J Pharmacol Exp Ther. 1994; 268(1): 417–426. 9. Gross G, Drescher K. (2012) The role of dopamine D-3 receptors in antipsychotic activity and cognitive functions. //Handb Exp Pharmacol 167–210. [PubMed] [Google Scholar]. 10. Gyertyán I, Kiss B, Sághy K, Laszy J, Szabó G, Szabados T, Gémesi LI, Pásztor G, Zájer-Balázs M, Kapás M, Csongor EA, Domány G, Tihanyi K, Szombathelyi Z. (2011) Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents.// Neurochem Int 59:925–935. [PubMed] [Google Scholar]. 11. Heidbreder C., Gardner E., Xi Z. et al. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence// Brain Res Rev. 2005 Jul;49(1): 77–105. 12. Heidbreder C., and Amy H. Newman Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders// Ann N Y Acad Sci. 2010 Feb;1187:4-34. doi: 10.1111/j.1749-6632.2009.05149.x. 13. Kiss B, Horváth A, Némethy Z, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. //J Pharmacol Exp Ther. 2010; 333(1): 328–340. 14. С.Н. Мосолов, П.В. Алфимов Роль дофаминовых D3-рецепторов в механизме действия современных антипсихотиков. Современная терапия психических расстройств. 2014; 1: 2-9. 15. Mészáros GP, Kapás M, Borsos M et al. (P.3.c.047) Pharmacokinetics of RGH-188, a new dopamine D3/D2 antagonist/partial agonist atypical antipsychotic, in healthy subjects. Eur Neuropsychopharmacol 2007; 17 (Suppl. 4): S451–S452. 16. Nasrallah HA1, Earley W2, Cutler AJ3, Wang Y2, Lu K2, Laszlovszky I4, Németh G4, Durgam S2. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis// BMC Psychiatry. 2017 Aug 24;17(1):305. doi: 10.1186/s12888-017-1459-z. 17. Neill JC, Grayson B, Kiss B, Gyertyán I, Ferguson P, Adham N. (2016) Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. //Eur Neuropsychopharmacol 26:3–14. [PubMed] [Google Scholar]. 18. Németh, G, Laszlovszky, I, Czobor, P. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. //Lancet 2017; 389: 1103–1113. 19. Papp M, Gruca P, Lason-Tyburkiewicz M, Adham N, Kiss B, Gyertyán I. (2014) Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression.// Behav Pharmacol 25:567–574. [PubMed] [Google Scholar]. 20. Román V1, Gyertyán I, Sághy K, Kiss B, Szombathelyi Z, Cariprazine (RGH-188), a D₃-preferring dopamine D₃/D₂ receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats.// Psychopharmacology (Berl). 2013 Mar;226(2):285-93. doi: 10.1007/s00213-012-2906-7. Epub 2012 Nov 9. 21. Larry O. Sanders, MD, John J. Miller, MD, Cariprazine May Decrease Substance Abuse in Patients With Bipolar I Disorder // https://www.psychiatrictimes.com/psychopharmacology/cariprazine-may-decrease-substance-abuse-patient.... 22. Sautel F, Griffon N, Levesque D, Pilon C, Schwartz J-C, Sokoloff P. A functional test identifies dopamine agonists selective for D3 versus D2 receptors. //Neuroreport. 1995; 6(2): 329–332. 23. Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, Stubbs B, Monaco F, Vieta E, Seeman MV, Correll CU, Carvalho AF. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.// Ther Clin Risk Manag. 2017 Jun 29;13:757-777. doi: 10.2147/TCRM.S117321. eCollection 2017. Review. PMID: 28721057. 24. Stahl, SM. Mechanism of action of cariprazine. //CNS Spectr. 2016; 21: 123–127. 25. Thanos PK, et al. The selective dopamine D3 receptor antagonist SB-277011-A attenuates ethanol consumption in ethanol preferring (P) and non-preferring (NP) rats.// Pharmacol. Biochem. Behav. 2005;81:190–197. 26. Thanos PK, et al. The effects of two highly selective dopamine D3 receptor antagonists (SB-277011A and NGB-2904) on food self-administration in a rodent model of obesity. Pharmacol. Biochem. Behav. 2008;89:499–507. 27. Veselinović T1, Paulzen M, Gründer G Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression.// Expert Rev Neurother. 2013 Nov;13(11):1141-59. doi: 10.1586/14737175.2013.853448. 28. Volkow ND, Wise RA. How can drug addiction help us understand obesity? //Nat. Neurosci. 2005;8: 555–560. 29. Watson D J, King MV, Gyertyan I, Kiss B, Adham N, Fone KC. (2016) The dopamine D(3)-preferring D(2)/D(3) dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia.// Eur Neuropsychopharmacol 26: 208–224. [PubMed] [Google Scholar]. 30. Zimnisky R, Chang G, Gyertyán I, Kiss B, Adham N, Schmauss C. (2013) Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse.// Psychopharmacology (Berl) 226:91–100. [PMC free article] [PubMed] [Google Scholar]. 31. ttps://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370.lbl.pdf 32. Инструкция по медицинскому применению препарата Реагила РУ ЛП-005405 от 18.042019. С инструкцией можно ознакомиться на сайте www.grls.rosminzdrav.ru. 33. Ю.В. Быков, Р.А. Беккер, П.В. Морозов Эффективность карипразина в лечении шизофрении, особенно с преобладанием негативной симптоматики. Психиатрия и психофармакотерапия том 20 №20 2018.